Clinical trial
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low…
NCT00193440 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193440 |
|---|---|
| Title | Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma |
| Official title | Phase II Trial of Rituximab and Short Duration Chemotherapy Followed by Zevalin as First-Line Treatment for Patients With Low Grade Follicular Non-Hodgkin's Lymphoma |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Biogen Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkins Lymphoma |
| Intervention type | Drug |
| Interventions | Rituximab, CHOP, CVP, Ibritumomab Tiuxetan |
| Enrollment | 40 |
| Start date | Apr 1, 2002 |
| Primary completion | Apr 1, 2004 |
| Completion | Jan 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Dec 30, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: